Adjuvants enhance vaccine immunity by various mechanisms, primarily by activating the innate immune system. Recent research has shown that many adjuvants enhance T and B cell responses through innate immune components rather than directly acting on lymphocytes. Adjuvants are used to increase the magnitude and quality of the adaptive immune response, providing protection against pathogens. Current adjuvants, such as alum, are effective for generating immunity against viral and bacterial infections, but there is a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines. The challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant antigens. Adjuvants are used to guide the type of adaptive response to produce the most effective immunity for specific pathogens. They are used clinically to increase vaccine response in the general population, increase seroconversion rates in populations with reduced responsiveness, facilitate smaller antigen doses, and permit fewer vaccine doses. Adjuvants also help achieve qualitative changes in the immune response, such as promoting specific types of immunity not effectively generated by nonadjuvanted antigens. Challenges in vaccine adjuvant development include generating protective CD8+ T cell responses to soluble proteins and developing adjuvants for therapeutic treatment of cancers and chronic viral infections. Innate immunity relies on pattern recognition receptors (PRRs) to detect microbial patterns, and adjuvants can engage these receptors to enhance immune responses. Adjuvants such as MF59 and AS03 are oil-in-water emulsions that stimulate stronger antibody responses and generate memory responses. ISCOMs, which are saponin-based adjuvants, enhance antigen uptake and induce strong antibody and T cell responses. Adjuvants targeting PRRs, such as TLR3, TLR4, TLR5, TLR7, and TLR9, have been developed to enhance immune responses. TLR3 and RLR ligands, such as dsRNA and viral RNA, activate innate immunity and enhance T and B cell responses. TLR4 ligands, such as MPL, are used in vaccines for hepatitis B and papilloma. TLR5 ligands, such as flagellin, can produce mixed Th1 and Th2 responses. TLR7 and TLR8 ligands, such as imidazoquinolines, activate TLR7 and TLR8 and enhance immune responses. TLR9 ligands, such as CpG-ODN, are used in vaccines to enhance antibody responses and Th1 cell immunity. Studies have shown that codelivery of antigens and PRR ligands enhances vaccine effectiveness. Adjuvants can work through direct and indirect actions on antigen-presenting cells (APCs). Multiple innate stimuli can be more effective than a single pathway. Formulations and PRR ligands can be combined to develop the most appropriate response. Animal modelsAdjuvants enhance vaccine immunity by various mechanisms, primarily by activating the innate immune system. Recent research has shown that many adjuvants enhance T and B cell responses through innate immune components rather than directly acting on lymphocytes. Adjuvants are used to increase the magnitude and quality of the adaptive immune response, providing protection against pathogens. Current adjuvants, such as alum, are effective for generating immunity against viral and bacterial infections, but there is a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines. The challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant antigens. Adjuvants are used to guide the type of adaptive response to produce the most effective immunity for specific pathogens. They are used clinically to increase vaccine response in the general population, increase seroconversion rates in populations with reduced responsiveness, facilitate smaller antigen doses, and permit fewer vaccine doses. Adjuvants also help achieve qualitative changes in the immune response, such as promoting specific types of immunity not effectively generated by nonadjuvanted antigens. Challenges in vaccine adjuvant development include generating protective CD8+ T cell responses to soluble proteins and developing adjuvants for therapeutic treatment of cancers and chronic viral infections. Innate immunity relies on pattern recognition receptors (PRRs) to detect microbial patterns, and adjuvants can engage these receptors to enhance immune responses. Adjuvants such as MF59 and AS03 are oil-in-water emulsions that stimulate stronger antibody responses and generate memory responses. ISCOMs, which are saponin-based adjuvants, enhance antigen uptake and induce strong antibody and T cell responses. Adjuvants targeting PRRs, such as TLR3, TLR4, TLR5, TLR7, and TLR9, have been developed to enhance immune responses. TLR3 and RLR ligands, such as dsRNA and viral RNA, activate innate immunity and enhance T and B cell responses. TLR4 ligands, such as MPL, are used in vaccines for hepatitis B and papilloma. TLR5 ligands, such as flagellin, can produce mixed Th1 and Th2 responses. TLR7 and TLR8 ligands, such as imidazoquinolines, activate TLR7 and TLR8 and enhance immune responses. TLR9 ligands, such as CpG-ODN, are used in vaccines to enhance antibody responses and Th1 cell immunity. Studies have shown that codelivery of antigens and PRR ligands enhances vaccine effectiveness. Adjuvants can work through direct and indirect actions on antigen-presenting cells (APCs). Multiple innate stimuli can be more effective than a single pathway. Formulations and PRR ligands can be combined to develop the most appropriate response. Animal models